Skip to main content
Lab in Liverpool)

MANUFACTURING

Manufacturing for Global Markets

One of the largest influenza vaccine companies in the world, CSL Seqirus operates state-of-the-art manufacturing facilities in three different continents and a globally integrated supply chain for the timely supply of influenza vaccine to customers around the world. We have one of the most comprehensive influenza vaccine portfolios in the industry, tailored to the needs of health care professionals and their patients.

As part of our heritage, in Australia CSL Seqirus plays a unique public health role, continuing a long legacy as the manufacturer and sole supplier of a range of products made for the Australian Government in the National Interest, including snake and spider antivenoms and Q fever vaccine.

Manufacturing and supply in numbers

We operate advanced production facilities in the US, the UK and Australia, and manufacture influenza vaccine using both egg- and cell-based technologies.

  • 1

    The only influenza vaccine manufacturing facility in Australia

  • 150 million

    ​6-month capacity for pandemic vaccine doses at our Holly Springs plant

  • Approx 650

    Employees at the UK’s largest biotechnology site in Liverpool

Our Global Manufacturing Network

Seqirus Global Presence

We’re geographically diverse

CSL Seqirus is one of the world’s largest influenza vaccine manufacturers with innovative technologies and differentiated products.

Learn more

Employees at Seqirus Holly Springs

CSL Seqirus first to reach large-scale manufacture of cell-based influenza vaccines

The accelerated development of CSL Seqirus’ cell-based manufacturing technology at its state-of-the-art manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just three years.

Watch video
Researchers at Seqirus Holly Springs

We’re constantly improving our methods and processes

Our technical development laboratories are co-located with our manufacturing facilities. They provide the scientific and technical capability to ensure CSL Seqirus products are the best defence for the world against influenza.

Learn more

AP-CRP-23-0001

Seqirus privacy statement
Seqirus privacy statement

This website contains content which is for New Zealand healthcare professionals only. By selecting this box you acknowledge that you are a new Zealand healthcare professional and accessing this website within the scope of your daily practice.